Session » RA – Animal Models Poster

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 982

A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice

9:00AM-11:00AM: Abstract Number: 981

Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models

9:00AM-11:00AM: Abstract Number: 987

Anti-citrullinated Protein Antibodies Induce Subclinical Inflammation, Bone Loss and Pain in Mice

9:00AM-11:00AM: Abstract Number: 977

Conditional Deletion of MKL1 Inhibits Osteoclast Formation and Bone Erosions in Collagen Induced Arthritis Mice

9:00AM-11:00AM: Abstract Number: 990

Development of a Novel Anti TNF-Steroid Antibody Drug Conjugate That Shows Promising Efficacy at Doses That Avoid Steroid Side Effects in a Mouse Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 983

Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection

9:00AM-11:00AM: Abstract Number: 991

Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides

9:00AM-11:00AM: Abstract Number: 992

Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 984

Important Role of CD11c+ Cells in Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 994

Increased Antibody and T-cell Responses Following Treatment of Collagen-Induced Arthritis in C57Bl/6 Mice with Organic Dust Inhalants

9:00AM-11:00AM: Abstract Number: 985

Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis

9:00AM-11:00AM: Abstract Number: 995

Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 978

Light Mediated Therapeutics in Arthritis

9:00AM-11:00AM: Abstract Number: 989

Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1001

Oral Collagen Type V Supplementation Inhibits Cartilage Degeneration in Experimental Arthritis

9:00AM-11:00AM: Abstract Number: 993

pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 979

Platelet Derived Growth Factor Receptor Alpha (PDGFRα) Blockade Inhibits Arthritis in Mice

9:00AM-11:00AM: Abstract Number: 1000

RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis

9:00AM-11:00AM: Abstract Number: 980

Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis

9:00AM-11:00AM: Abstract Number: 998

Stimulation of Splenic Neurovascular Bundle Protect Mice from Developing Collagen-induced Arthritis

9:00AM-11:00AM: Abstract Number: 997

Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis

9:00AM-11:00AM: Abstract Number: 999

Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy

9:00AM-11:00AM: Abstract Number: 996

The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages

9:00AM-11:00AM: Abstract Number: 986

Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levelsin a Rat Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 988

Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].